Autologous Cell Therapy for Ischemic Heart Failure
A Prospective, Multicenter, Feasibility Study of Autologous Muscle-derived Cell (AMDC) Transplantation for Treatment of Advanced Ischemic Heart Failure
Sponsor: Cook MyoSite
Terminated
This trial was terminated. No reason was provided.
Other Ischemic Heart Disease trials with similar outcome
This PHASE1/PHASE2 trial investigates Ischemic Heart Disease and is currently terminated or withdrawn. Cook MyoSite leads this study, which shows 8 recorded versions since 2011 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Sep 2021 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
-
Jan 2021 — Sep 2021 [monthly]
Terminated PHASE1_PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Terminated PHASE1_PHASE2
▶ Show 3 earlier versions
-
Jun 2018 — Dec 2020 [monthly]
Terminated PHASE1_PHASE2
-
Aug 2017 — Jun 2018 [monthly]
Terminated PHASE1_PHASE2
-
Jan 2017 — Aug 2017 [monthly]
Terminated PHASE1_PHASE2
First recorded
Feb 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cook MyoSite
For direct contact, visit the study record on ClinicalTrials.gov .